BioMedica Stops TroVax Trials in US
Oxford BioMedica has announced that they have halted their mid-stage trials of TroVax in America. The organisation confirmed that they would be stopping the US portion of trials to evaluate the activity of TroVax (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC). The market didn’t respond well, with BioMedica’s share price falling by